Ipidacrine efficacy in diabetic polyneuropathy complex treatment: A review

Cover Page

Cite item

Full Text

Abstract

Diabetic polyneuropathy (DPN) is a common neurological complication of diabetes mellitus. The most common DPN type is distal symmetric, predominantly sensory, polyneuropathy (DSPN), often accompanied by pain syndrome. This article is aimed to evaluate of ipidacrine (Ipigrix) efficacy in complex DSPN therapy. The dynamics of clinical and neurophysiological manifestations of DPN in the form of the appearance of previously absent tendon reflexes, a decrease in the area and severity of sensory disturbances, the intensity of neuropathic pain, an increase in the amplitude of motor and sensory responses in response to stimulation of peripheral nerves indicates the activation of reinnervation processes against the background of therapy using ipidacrine. Assessing the positive effect on the restoration of the structure and function of peripheral nerves, good tolerability and safety of ipidacrine (Ipigrix), it is possible to recommend the drug in patients with DSPN.

About the authors

Olga E. Zinovyeva

Sechenov First Moscow State Medical University (Sechenov University)

Email: zinovyevaolga@yandex.ru
ORCID iD: 0000-0001-5937-9463

D. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Pavel D. Egorov

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: egorovpd@vk.com
ORCID iD: 0000-0003-0238-1604

Clinical Resident, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Anna I. Penkina

Sechenov First Moscow State Medical University (Sechenov University)

Email: solt0206@mail.ru

Student, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Samir S. Guseinov

Sechenov First Moscow State Medical University (Sechenov University)

Email: samir.guseinov@inbox.ru

Student, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

References

  1. IDF Diabetes Atlas, 9th edition. Brussels: International Diabetes Federation, 2019. Available at: https://www.diabetesatlas.org/en. Accessed: 13.02.2022.
  2. Neeland IJ, Patel KV. Diabetes: Key Markers of Injury and Prognosis. In: Biomarkers in Cardiovascular Disease. Ed. V Nambi. Netherlands: Elsevier, 2019; p. 41-51. doi: 10.1016/B978-0-323-54835-9.00004-1
  3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diabetes Rep. 2019;19(10):86. doi: 10.1007/s11892-019-1212-8
  4. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44 (Suppl. 1):S15-33. doi: 10.2337/dc21-S002
  5. Маслова О.В., Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет. 2011;3:6-11 [Maslova OV, Suntsov YuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11 (in Russian)].
  6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93. doi: 10.2337/dc10-1303
  7. Gordon SA, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn). 2012;18(1):60-84. doi: 10.1212/01.CON.0000411568.34085.3e
  8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817-24. doi: 10.1212/wnl.43.4.817
  9. Зиновьева О.Е., Остроумова Т.М., Коняшова М.В., Горбачев Н.А. Диагностика и лечение поражений периферической нервной системы у пациентов с предиабетом. Неврология, нейропсихиатрия и психосоматика. 2021;13(5):116-22 [Zinovyeva OE, Ostroumova TM, Koniashova MV, Gorbachev NA. Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):116-22 (in Russian)].
  10. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42. doi: 10.1007/s11940-005-0004-4
  11. Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to- practice. Int J Gen Med. 2012;5:129-34. doi: 10.2147/IJGM.S10328
  12. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-9. doi: 10.2337/diacare.17.11.1281
  13. Herman WH, Pop-Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937-44. doi: 10.1111/j.1464-5491.2012.03644.x
  14. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454-63. doi: 10.2337/db13-1819
  15. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. doi: 10.1002/dmrr.1225
  16. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14. doi: 10.1007/s11154-008-9104-2
  17. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. doi: 10.1002/ame2.12001
  18. Park S, Kang HJ, Jeon JH, et al. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252-62. doi: 10.1007/s12272-019-01130-3
  19. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222. doi: 10.3390/biom5010194
  20. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14(10):953-61. doi: 10.2174/138161208784139774
  21. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst. 2005;10(2):144-57. doi: 10.1111/j.1085-9489.2005.0010205.x
  22. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired Axonal Regeneration in Diabetes. Perspective on the Underlying Mechanism from In Vivo and In Vitro Experimental Studies. Front Endocrinol (Lausanne). 2017;8:12. doi: 10.3389/fendo.2017.00012
  23. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2004;9(1):26-53. doi: 10.1111/j.1085-9489.2004.09105.x
  24. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561-8. doi: 10.7326/0003-4819-122-8-199504150-00001
  25. Аметов А.С., Солуянова Т.Н. Преимущества бенфотиамина в лечении диабетической полинейропатии. Эффективная фармакотерапия в эндокринологии. 2008;1:1-4 [Ametov AS, Soluianova TN. Preimushchestva benfotiamina v lechenii diabeticheskoi polineiropatii. Effektivnaia farmakoterapiia v endokrinologii. 2008;1:1-4 (in Russian)].
  26. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70. doi: 10.2337/dc06-1216
  27. Кукушкин М.Л., Карпова М.Н., Кузнецова Л.В., Клишина Н.Ю. Обезболивающее действие ипидакрина. Российский журнал боли. 2019;17(3):29-33 [Kukushkin ML, Karpova MN, Kuznetsova LV, Klishina NYu. Analgesic effect ipidacrine. Russian journal of pain. 2019;17(3):29-33 (in Russian)]. doi: 10.25731/RASP.2019.03.29
  28. Строков И.А., Зиновьева О.Е., Баринов А.Н., Ахмеджанова Л.Т. Нейромидин в лечении диабетической полиневропатии. Неврологический журнал. 2007;12(6):52-5 [Strokov IA, Zinov'eva OE, Barinov AN, Akhmedzhanova LT. Neiromidin v lechenii diabeticheskoi polinevropatii. Nevrologicheskii zhurnal. 2007;12(6):52-5 (in Russian)].
  29. Магомедова А.М., Меркулов Ю.А., Биглова А.Н., и др. Пациент с онемением в руках на амбулаторном приеме невролога: старые предрассудки, новые стратегии дифференциальной диагностики и лечения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(3):16-23 [Magomedova AM, Merkulov YA, Biglova AN, et al. An outpatient with hand numbness: old prejudices, new strategies of differential diagnosis and treatment. Zhurnal Nevrologii i Psikhiatrii im. SS Korsakova. 2019;119(3):16-23 (in Russian)]. doi: 10.17116/jnevro201911903116
  30. Живолупов С.А., Самарцев И.Н. Нейропластичность: патофизиологические аспекты и возможности терапевтической модуляции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(4):78-85 [Zhivolupov SA, Samartsev IN. Neuroplasticity: pathophysiological patterns and perspectives of therapeutic modulation. Zhurnal Nevrologii i Psikhiatrii Im. SS Korsakova. 2009;109(4):78-85 (in Russian)].
  31. Катунина Е.А., Аванесова О.В., Пестовская О.Р., и др. Применение ингибиторов ацетилхолинэстеразы при лечении заболеваний периферической нервной системы. Фарматека. 2009;15:51-7 [Katunina EA, Avanesova OV, Pestovskaia OR, et al. Primenenie ingibitorov atsetilkholinesterazy pri lechenii zabolevanii perifericheskoi nervnoi sistemy. Farmateka. 2009;15:51-7 (in Russian)].
  32. Рачин А.П., Шаров М.Н., Рачин С.А., Прокофьева Ю.С. Наблюдательное исследование по оценке эффективности применения препарата Ипигрикс при диабетической полиневропатии (исследование НИРВАНА). Нервные болезни. 2018;2:26-30 [Rachin AP, Sharov MN, Rachin SA, Prokof'eva IuS. Nabliudatel'noe issledovanie po otsenke effektivnosti primeneniia preparata Ipigriks pri diabeticheskoi polinevropatii (issledovanie NIRVANA). Nervnye bolezni. 2018;2:26-30 (in Russian)]. doi: 10.24411/2226-0757-2018-12019

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies